Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical HSCT with CD3/CD19 Depletion for Severe Aplastic Anemia
NCT01105273Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Jul 2009
- Primary completion
- Jul 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD3/CD19 depleted hematopoietic stem cells in aplastic anemia, sponsored by Asan Medical Center. Primary endpoint: Engraftment rate and survival at 2 years. Started Jul 2009; status: completed.
02
Drugs
CD3/CD19 depleted hematopoietic stem cells
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT01105273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01105273.